Navigation Links
Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results

XIANYANG, China, May 17 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (Nasdaq: BSPM) ("Biostar" or "the Company"), a Xianyang- based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules ("Xin Aoxing"), and a variety of pharmaceutical products, today announced financial results of the first quarter ended March 31, 2010.

    -- Q1 2010 revenue increased 66.0% to $12.4 million
    -- Q1 gross margins were 77.0%, a 1,270-basis point improvement
    -- Q1 2010 Non-GAAP adjusted net income increased 32.1% to $2.4 million
       with adjusted EPS of $0.09
    -- Biostar reiterates guidance for 2010: Revenue expected to be between
       $80.0 to $82.0 million and net income between $18.0 to $20.0 million


    First Quarter 2010 Results (unaudited)

                                   Q1 2010            Q1 2009       CHANGE
    Net Sales                  $12.4 million       $7.4 million     +66.0%
    Gross Profit                $9.5 million       $4.8 million     +98.9%
    GAAP Net Income             $2.3 million       $1.8 million     +23.7%
    Adjusted Non-GAAP Net
     Income*                    $2.4 million       $1.8 million     +32.1%
    GAAP EPS (Diluted)                 $0.08              $0.08        +0%
    Adjusted Non-GAAP EPS
     (Diluted)*                        $0.09              $0.08     +12.5%

    * Excluding non-cash stock-based compensation charge of $0.2 million for
      Q1 2010.  For more information about the non-GAAP financial measures
      contained in this press release, please see "About Non-GAAP Financial
      Measures" below.

First Quarter 2010 Financial Results

Revenue for the first quarter of 2010 increased 66.0% to approximately $12.4 million compared to $7.4 million for the first quarter of 2009. The increase was primarily due to Biostar's flagship product, Xin Aoxing Oleanolic Acid Capsule ("Xin Aoxing"), which saw increased sales by 138.2% to $9.2 million with a gross margin of 85.1%, compared to $3.9 million in the first quarter of 2009. Sales of Xin Aoxing represented 74.4% of total revenues and benefited from the expansion into the Beijing and Shanghai markets during the first quarter of 2010, in addition to the implementation of a retail-direct selling strategy to select high-volume pharmacies who accept direct shipments from the Company's Xianyang-based production facility. Another notable contributor from Biostar's portfolio was its Taohuasan Pediatrics Medicine, which contributed $1.0 million in revenue in the first quarter of 2010, an increase of 13.1% compared to $0.9 million in the first quarter of 2009. The Company continued its expansion into rural communities in China with products now being sold at the Company's rural supply network of approximately 6,000 locations out of a target market which includes an estimated 10,000 total locations.

Cost of goods sold for the three months ended March 31, 2010 was approximately $2.8 million or 23.0% of revenues, as compared to $2.7 million or 35.7% of revenues for the three months ended March 31, 2009. Gross profits for the first quarter of 2010 were $9.5 million with gross margins of 77.0%, compared to $4.8 million in gross profit and gross margins of 64.3% for the first quarter of 2009. The increase in gross margins was due to the increased sales volumes of Xin Aoxing and Taohuasan as wells as lower raw material costs for Xin Aoxing experienced in the first quarter of 2010. Gross profits increased by 98.9% for the three months ended March 31, 2010 as compared to the same period in 2009.

Operating expenses for the three months ended March 31, 2010 were approximately $6.4 million, an increase of 157.7% compared to the same period in 2009. Selling and distribution cost increased 197% to $5.6 million in the first quarter of 2010, compared to $1.9 million in the same period in 2009. The increase in selling cost is primarily due to $2.2 million in incremental advertising and promotional efforts which included billboards, newsprints and in-store advertising designed to drive sales in existing and new markets and to promote brand awareness of Xin Aoxing. These increased sales activities drove higher commissions and travel expenses, which increased $1.1 million and $0.3 million, respectively. In addition, the Company incurred non-cash equity compensation charge of $0.2 million in the first quarter of 2010, which was not present for the same period in 2009.

Operating income for the first quarter of 2010 totaled approximately $3.1 million, a 35.7% increase from $2.3 million reported for the first quarter of 2009. Operating margins were 25.3% and 31.0% for the first quarter of 2010 and 2009, respectively. The decrease was mainly attributed to the increase of SG&A in the first quarter of 2010. Excluding the non-cash equity compensation charge of $0.2 million recorded during the first quarter of 2010, adjusted operating income for the first quarter is $3.3 million with operation margins of 26.6%.

Net income was approximately $2.3 million for the first quarter of 2010, a 23.7% increase compared to $1.8 million for the first quarter of 2009. Diluted earnings per share were $0.08 for the first quarter of 2010 compared to $0.08 for the first quarter of 2009, based upon 27.3 million and 23.5 million diluted common shares outstanding, respectively. Adjusted Non-GAAP net income for the first quarter was $2.4 million, or $0.09 per diluted common share based on 27.3 million diluted common shares outstanding for the first quarter of 2010. The Company's effective tax rate was at 27.6% for the first quarter of 2010.

"We are pleased to report another quarter of strong revenue growth, as Biostar gains further brand recognition and awareness for our Xin Aoxing Capsules. With momentum in several key markets, we are confident that this flagship product is becoming known as one of the major medical treatments for Hepatitis B in China," commented Ronghua Wang, Chairman and Chief Executive Officer of Biostar. "We are optimistic that with our continued expansion into new markets, supported by comprehensive marketing and distribution strategies, including direct sales, we are in position to leverage our product portfolio for optimal growth." Wang concluded.

Balance Sheet and Cash Flow

Cash and cash equivalents totaled $8.6 million on March 31, 2010, compared to $8.6 million on December 31, 2009. Accounts receivable balance was approximately $20.8 million on March 31, 2010, versus approximately $19.8 million on December 31, 2009. Days sales outstanding (DSO) were at 149 days. The Company had a current ratio of 5.7 to 1 and stockholders' equity of $43.4 million, with total assets of $48.9 million versus total liabilities of $5.6 million on March 31, 2010.

For the first three months of 2010, the Company generated $0.6 million in cash from operations versus $0.06 million used in operations reported for the same period in 2009.

Business Developments

As of March 31, 2010, Biostar has expended its rural supply network to approximately 6,000 sales outlets.

On April 27, Biostar addressed and resolved a concern that its main product, Xin Aoxing, was to be suspended from selling by the local State Food and Drug Administration (SFDA) due to non-compliance with approved advertising use.

On April 23, 2010, Biostar was approved by NASDAQ to list its common stock on the NASDAQ Global Market and commenced trading under the ticker symbol BSPM.

On April 12, 2010, Biostar completed Chinese Military Drug Administration clinical trials for Zushima Analgesic Aerosol Spray ("Zushima"). Zushima is a traditional Chinese herbal product used to relieve pain through a topical application of the medicine to affected areas or closed wounds. Zushima spray can also be used in the treatment of certain rheumatic conditions. The product was classified as "Specially Needed Drug" by the Chinese Military Drug Administration and will also be available to the public.

On March 29, 2010, Biostar officially took control over the assets of Xi'an Mei pude Bio-Technology Co., Ltd., a Xi'an-based medical equipment and nutrients manufacturer ("Meipude"). Biostar is working on a production marketing program and anticipates starting sales using the acquired assets in May 2010.

Conference Call

The Company will host a conference call to discuss the 2010 first quarter financial results on Monday, May 17, 2010 at 9:30 a.m. ET. Interested participants should call +1-877-941-4775 within the United States, or US +1- 480-629-9763 if calling internationally. The conference ID is 4302147. It is advisable to dial in approximately 5-10 minutes prior to 9:30 a.m. ET. This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at or at the following link: . To access the web cast, you will need to have the Windows Media Player on your desktop. For the free download of the Media Player please visit: .

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary in China, develops, manufactures and markets pharmaceutical and medical nutrient products for a variety of diseases and conditions. The Company's most popular product is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar manufactures two broad-based OTC products, two prescription-based pharmaceuticals and thirteen nutrients. The Company has adopted international standards and is in the process of applying for two patents.

Safe Harbor

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our S-1 dated June 27, 2008, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, our 10-K for the year ended December 31, 2008, and other recent filings. These filings are available at . We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

About Non-GAAP Financial Measures

To supplement the Company's consolidated financial statements, which statements are prepared and presented in accordance with GAAP, we use the following non-GAAP financial measures: non-GAAP adjusted net income, and non- GAAP adjusted EPS. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. The Company uses these non-GAAP financial measures for financial and operational decision making and as a means to evaluate period-to-period comparisons. Management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the Company's performance and liquidity by excluding certain expenses and expenditures that may not be indicative of "recurring core business operating results", meaning operating performance excluding non-cash amortization charges for intangibles. China Marine believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing performance and when planning, forecasting and analyzing future periods. These non-GAAP financial measures also facilitate management's internal comparisons to historical performance and liquidity as well as comparisons to competitors' operating results. The Company believes these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making and (2) they are used by our institutional investors and the analyst community to help them analyze the health of the business.

    For further information, contact:

     Ms. Elaine Zhao, CFO
     Tel:   +1-626-456-2789

     John Mattio
     HC International, Inc.
     Tel:   US +1-203-616-5144

                        BIOSTAR PHARMACEUTICALS, INC.
                         CONSOLIDATED BALANCE SHEETS

                                                March 31,       December 31,
                                                  2010              2009
                                              (Unaudited)         (Audited)
    Current Assets
    Cash and cash equivalents                 $8,642,418          $8,577,704
    Accounts receivable                       20,837,401          19,803,434
    Inventories                                  564,955             340,078
    Prepaid expenses and other receivables     1,487,143           1,500,327
    Total Current Assets                      31,531,917          30,221,543

    Deposits                                     877,693           1,316,328
    Property, plant and equipment, net         5,202,236           4,340,917
    Intangible assets, net                    11,314,977          11,131,681

    Total Assets                             $48,926,823         $47,010,469


    Current Liabilities
    Accounts payable and accrued expenses     $4,005,676          $3,559,281
    Value-added tax payable                      628,908           1,050,051
    Income tax payable                           920,079           1,481,266
    Total Current Liabilities                  5,554,663           6,090,598

    Commitment and contingencies

    Stockholders' Equity
    Series B, convertible preferred
     stock, $0.001 par value, 5,000,000 shares
     authorized, 1,467,317 and 3,060,000
     shares issued and outstanding at March 31,
     2010 and December 31, 2009                    1,467               3,060
    Common stock, $.001 par value, 100,000,000
     shares authorized, 25,820,119 and
     23,374,799 shares issued and outstanding
     at March 31, 2010 and December 31, 2009      25,820              23,375
    Additional paid-in capital                19,992,542          19,801,366
    Statutory reserve                          3,119,132           2,860,685
    Retained earnings                         19,553,544          17,548,676
    Accumulated other comprehensive income       679,655             682,709
    Total Stockholders' Equity                43,372,160          40,919,871

    Total Liabilities and Stockholders'
     Equity                                  $48,926,823         $47,010,469

                        BIOSTAR PHARMACEUTICALS, INC.

                                               Three Months Ended March 31,
                                                2010                 2009
    Sales, net                              $12,363,175           $7,447,664

    Cost of sales                             2,840,426            2,658,807

    Gross profit                              9,522,749            4,788,857

    Operating expenses:
    Selling and distribution                  5,609,561            1,888,182
    General and administrative                  625,722              591,802
    Stock-based compensation                    154,490                   --
    Total operating expenses                  6,389,773            2,479,984

    Income from operations                    3,132,976            2,308,873

    Other Income (Expense)
    Interest income                               3,686                  310
    Other expense                                (6,131)                  --
    Foreign exchange loss                        (5,641)                  --
    Total Other Income (Expense)                 (8,086)                 310

    Income before income taxes                3,124,890            2,309,183

    Provision for income taxes                  861,575              480,151

    Net income                               $2,263,315           $1,829,032

    Net income per common stock
    Basic                                         $0.09                $0.08
    Diluted                                       $0.08                $0.08

    Weighted average number of common
     stocks outstanding
    Basic                                    25,129,674           23,240,899
    Diluted                                  27,341,138           23,509,458

                        BIOSTAR PHARMACEUTICALS, INC.

                                                Three Months Ended March 31,
                                                     2010          2009
    Net income                                   $2,263,315     $1,829,032
    Adjustments to reconcile net income to
     net cash provided by (used in) operating
    Depreciation and amortization                   138,403        166,269
    Stock-based compensation                        154,490             --
    Changes in operating assets and liabilities:
    Accounts receivable                          (1,030,791)    (2,123,128)
    Inventories                                    (224,825)        11,535
    Prepaid expenses and other receivables           13,420       (387,054)
    Accounts payable and accrued expenses           248,346        371,398
    Customer advances                                    --        (36,193)
    VAT payable                                    (421,316)        37,044
    Income tax payable                             (561,431)        66,487
    Net cash provided by (used in) operating
     activities                                     579,611        (64,610)

    Purchase of property, plant and equipment      (281,542)            --
    Acquisition of proprietary technologies        (265,153)            --
    Net cash used in investing activities          (546,695)            --

    Proceeds from issuance of common stock           37,537             --
    Net cash provided by financing activities        37,537             --

    Effect of exchange rate changes on
     cash and cash equivalents                       (5,739)           939

    Net Increase (Decrease) in cash and
     cash equivalents                                64,714        (63,671)

    Cash and cash equivalents, beginning
     balance                                      8,577,704        758,316

    Cash and cash equivalents, ending
     balance                                     $8,642,418       $694,645

    Interest payments                                   $--            $--
    Income tax payments                          $1,423,006       $413,665

    Conversion of preferred stock to common
     stock                                           $1,593            $--
    Cashless exercise of warrants                      $815            $--
    Prior year deposit paid for acquisition
     of property and equipment                     $438,851            $--
    Payable for acquisition of property and
     equipment and intangible assets               $197,483            $--

SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
2. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
3. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
4. Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program
5. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
6. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
7. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
8. Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
9. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
10. Poniard Pharmaceuticals, Inc. to Present Additional Cancer Treatment Data Found Significant by TapeBeat.Com Investors
11. Lotus Pharmaceuticals, Inc. Appoints OTC Division Head
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015 Cepheid (Nasdaq: CPHD ... at the Piper Jaffray Healthcare Conference in ... Company is reaffirming its outlook for the fourth quarter ... addition to discussing longer term business model expectations. ... Officer.  "We continue to be the fastest growing company ...
(Date:12/1/2015)... , December 1, 2015 ... of the  "2016 U.K. Virology and Bacteriology ... for 100 Tests, Supplier Shares by Test, ... to their offering.  --> ... "2016 U.K. Virology and Bacteriology Testing Market: ...
(Date:11/30/2015)... MIAMI (PRWEB) , ... November 30, 2015 , ... Global Stem Cells Group ... new clinics in the cities of Arica and Iquique in northern Chile. The facilities are ... clinics offer the most advanced protocols and techniques in stem cell medicine to patients from ...
(Date:11/30/2015)... ALBANY, N.Y. , Nov. 30, 2015 /PRNewswire-USNewswire/ ... led by assistant chemistry professor Jan Halámek, is ... level.   --> ...   --> ... researchers at UAlbany have discovered a straightforward concept ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... 2015 Daon, a global leader in mobile ... a new version of its IdentityX Platform , ... America have already installed IdentityX v4.0 and ... FIDO UAF certified server component as an ... FIDO features. These customers include some of the largest ...
Breaking Biology News(10 mins):